Prothena to Report Third Quarter 2022 Financial Results on November 3rd DUBLIN, Ireland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical...
Prothena to Participate in Upcoming Healthcare Conferences DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology...
Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc...
Prothena Reports Second Quarter 2022 Financial Results and Business Highlights Net cash used in operating and investing activities was $35.5 million in the second quarter and $72.9 million...
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical...
Prothena to Report Second Quarter 2022 Financial Results on August 8th DUBLIN, Ireland, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical...
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland, July 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical...
Prothena to Participate in Jefferies Healthcare Conference DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology...
Prothena Reports First Quarter 2022 Financial Results and Business Highlights Net cash used in operating and investing activities was $37.4 million in the first quarter; quarter-end cash and...
Prothena to Report First Quarter 2022 Financial Results on May 5th DUBLIN, Ireland, April 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 14.65 | 14.65 | 14.65 | 455 | 14.65 | DE |
4 | 0 | 0 | 14.65 | 14.65 | 14.65 | 1171 | 14.65 | DE |
12 | 0 | 0 | 14.65 | 14.65 | 14.65 | 1100 | 14.65 | DE |
26 | 0 | 0 | 14.65 | 14.65 | 14.65 | 630 | 14.65 | DE |
52 | 0 | 0 | 14.65 | 14.65 | 14.65 | 812 | 14.65 | DE |
156 | 0 | 0 | 14.65 | 14.65 | 14.65 | 299 | 14.65 | DE |
260 | 0 | 0 | 14.65 | 14.65 | 14.65 | 200 | 14.65 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales